RenovoRx
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.renovorx.com
Intra-arterial Gemcitabine Vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Phase 3
Recruiting
- Conditions
- Locally Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- RenovoRx
- Target Recruit Count
- 190
- Registration Number
- NCT03257033
- Locations
- 🇺🇸
Feinstein Institutes for Medical Research - Northwell Health, Manhasset, New York, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸VA Loma Linda Healthcare System, Loma Linda, California, United States
Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter
Completed
- Conditions
- Pancreatic Neoplasms
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- RenovoRx
- Target Recruit Count
- 25
- Registration Number
- NCT02591082
- Locations
- 🇺🇸
Good Samaritan Hospital, San Jose, California, United States
🇺🇸Fawcett Memorial Hospital, Port Charlotte, Florida, United States
🇺🇸Florida Hospital, Tampa, Florida, United States
A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Gemcitabine, local delivery
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- RenovoRx
- Target Recruit Count
- 20
- Registration Number
- NCT02237157
- Locations
- 🇺🇸
El Camino Hospital, Oncology, Mountain View, California, United States
🇺🇸Florida Hospital, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath